Skip To Main Content
Enlivex Therapeutics on Muck Rack

Enlivex Therapeutics

As seen in: Olean Times Herald, The Salamanca Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Enlivex Therapeutics’s profile

Articles by Enlivex Therapeutics

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

|
By Enlivex Therapeutics
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering AllocetraTM, the Company’s immunotherapy product candidate.
Open in Who Shared View Duplicates (25) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

|
By Enlivex Therapeutics
| Research Pool
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled.
Open in Who Shared View Duplicates (34) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex to Present at the 2023 Jefferies Healthcare Conference

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 11:30 AM Eastern Time. A webcast of the presentation will be available at , and will be archived for 90 days.
Open in Who Shared View Duplicates (128) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell Gene Therapy | ResearchPool

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (59) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy | ResearchPool

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (57) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy Nes-Ziona, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application number 16/076,026.
Open in Who Shared Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Appoints Andrew Singer to its Board of Directors

|
By Enlivex Therapeutics
| Research Pool
Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital Markets Led financing, partnering and M&A biopharmaceutical transactions in excess of $13 billion Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (33) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors, a part of the Company’s ongoing Phase...
Open in Who Shared View Duplicates (36) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a clinical collaboration with BeiGene.
Open in Who Shared View Duplicates (33) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers Nes-Ziona, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (32) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial Nes-Ziona, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (36) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS |

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (32) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (37) Issue with article?

EQS Group AG - Enlivex Therapeutics (ENLV) EQS-News: A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics EQS-News: A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial EQS-News: Enlivex Therapeutics, Ltd. A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial 07.12.2022 / 14:40 CET/CEST The issuer is solely responsible for the content of this announcement. Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (16) Issue with article?

EQS Group AG - Enlivex Therapeutics (ENLV) EQS-News: Whats Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

|
By Enlivex Therapeutics
| Research Pool
EQS-News: Enlivex Therapeutics, Ltd. What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers 06.12.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. Today, there are several potential applications of cell therapies.
Open in Who Shared View Duplicates (19) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

|
By Enlivex Therapeutics
| Research Pool
Received frozen-formulation Allocetra™ IND clearance from The U.S. Food And Drug Administration (FDA) for treatment of patients with advanced solid tumors The protocol of the IND includes intravenous administration of frozen-formulation Allocetra™, stand-alone, and in combination with a PD1 checkpoint inhibitor, to a study population that encompasses adult patients with advanced, unresectable or metastatic solid tumors that have relapsed or have been refractory to available approved...
Open in Who Shared View Duplicates (14) Issue with article?

EQS Group AG - Enlivex Therapeutics (ENLV) EQS-News: Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics EQS-News: Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors EQS-News: Enlivex Therapeutics, Ltd. Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors 01.12.2022 / 20:00 CET/CEST The issuer is solely responsible for the content of this announcement.
Open in Who Shared View Duplicates (47) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with a PD1 checkpoint inhibitor in a murine model of ovarian cancer, and additional models that demonstrated statistically...
Open in Who Shared View Duplicates (12) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors Multi-center trial of AllocetraTM in advanced solid tumor patients AllocetraTM is administered to the patients either intravenously or locally, depending upon tumor locations, as both monotherapy and in combination with anti-PD1 Trial builds on encouraging preclinical studies conducted...
Open in Who Shared View Duplicates (11) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a poster presentation at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer, which is taking place both virtually and in-person from November 8, 2022 through November 12, 2022 in Boston, Massachusetts.
Open in Who Shared View Duplicates (7) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022. Enlivex’s presentation will take place at 2:30 PM ET on October 06, 2022.
Open in Who Shared View Duplicates (20) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex to Present at Upcoming Investor and Media Conferences

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following investor and media conferences in September.
Open in Who Shared View Duplicates (9) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022 Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a substantial and statistically significant survival benefit in a murine mesothelioma...
Open in Who Shared View Duplicates (11) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy Nes-Ziona, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (10) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells Nes-Ziona, Israel, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (15) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

|
By Enlivex Therapeutics
ENLV Enlivex Therapeutics Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece.
Open in Who Shared View Duplicates (12) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

|
By Enlivex Therapeutics
| Research Pool
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancers Received Israeli Ministry of Health approval to initiate a Phase I/II trial evaluating Allocetra™ alone and in combination with a PD1 checkpoint inhibitor in patients with advanced solid tumors.
Open in Who Shared View Duplicates (15) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with PD1 checkpoint inhibition in a murine model of ovarian...
Open in Who Shared View Duplicates (12) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™ Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (14) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex to Present at the 2022 Jefferies Healthcare Conference

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 1:00 PM Eastern Time.
Open in Who Shared View Duplicates (5) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancer

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers Trial will be the first clinical study of Allocetra™ in patients with cancer, following encouraging , and Nes-Ziona, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (5) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annu

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting Stand-alone therapy with PD1 checkpoint inhibitors has shown limited efficacy against ovarian cancer, with response rates in prior clincical trials ranging from 7-15%.
Open in Who Shared View Duplicates (7) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients Grant provides $1.2 million in non-dilutive funding for 2022 sepsis clinical trial expenses To date, Enlivex has received a total of $7.8 million in non-dilutive grants from the Israel Innovation Authority, excluding this new grant Nes Ziona, Israel, May 25, 2022 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (7) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

|
By Enlivex Therapeutics
| Research Pool
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (11) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex to Present at the H.C. Wainwright Global Investment Conference

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will present a corporate overview and participate in virtual one-on-one investor meetings during the H.C. Wainwright Global Investment Conference, which is taking place from May 23 – 26, 2022.
Open in Who Shared View Duplicates (7) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Upcoming May Conference Presentations

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will be presenting scientific and clinical overviews in three oral presentations at the and the . Details on the presentations are below.
Open in Who Shared View Duplicates (5) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy.
Open in Who Shared View Duplicates (15) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each patent provides Enlivex with added intellectual property (IP) protection in the United States until at least 2036 with respect to claims covering methods of treating sepsis with AllocetraTM.
Open in Who Shared View Duplicates (14) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Nes-Ziona, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Open in Who Shared View Duplicates (6) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic Business Updates | ResearchPool

|
By Enlivex Therapeutics
| Research Pool
ENLV Enlivex Therapeutics Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex’s R&D efforts during the last two years, was successfully completed in Q1 2022, twelve months ahead of schedule Frozen formulation Allocetra™ is expected to vastly improve the product’s shelf-life, shipping logistics,...
Open in Who Shared View Duplicates (8) Issue with article?

Thinking about buying stock in Solid Biosciences, Enlivex Therapeutics, Sirius XM, Sundial Growers, or E*TRADE Financial?

|
By Solid Biosciences, Enlivex Therapeutics, Sirius XM
| Olean Times Herald Verified
Advance VotingAllegany CountyBusinessCattaraugus CountyCrimeLocalNationStateWestern New YorkWorld News in your Inbox! Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. Ads to Go Would you like to receive our ads to go? Sign Up Today! Breaking News Would you like to receive our breaking news? Sign up today! Circulation Promotions and Contests Want to receive notice about our circulation promotions and contests?
Open in Who Shared View Duplicates (52) Issue with article?

Thinking about buying stock in Solid Biosciences, Enlivex Therapeutics, Sirius XM, Sundial Growers, or E*TRADE Financial?

|
By Solid Biosciences, Sirius XM, Enlivex Therapeutics
| cnweekly.com
So often, when a film starts off stating that it's "Based on" or "Inspired by" a true story, I find that I'm bracing myself, preparing to jot down notes on certain overly dramatic incidents, then Google them when I get home, proving that the film took too many liberties with the facts. I've always known that it's a pointless exercise. If I want the absolute truth in a movie, I'll stick with documentaries (though many of those are suspect, too).
Open in Who Shared View Duplicates (2) Issue with article?

Thinking about buying stock in Solid Biosciences, Enlivex Therapeutics, Sirius XM, Sundial Growers, or E*TRADE Financial?

|
By Solid Biosciences, Enlivex Therapeutics, Sirius XM
| The Salamanca Press Verified
TownNews.com Content Exchange NEW YORK, Oct. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLDB, ENLV, SIRI, SNDL, and ETFC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
Open in Who Shared Issue with article?
Show More